BMT CTN Protocol 0401 -- Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-Cell Non-Hodgkin’s Lymphoma

Below are protocol-related doucments, which may be periodically updated.

• Protocol synopsis, version 7.0 dated January 14, 2009
• Protocol, version 7.0 dated January 14, 2009
• Summary of protocol changes (version 6.0 to 7.0)
• Informed consent, version 7.0 dated January 14, 2009
• Educational Material
• Informational Flyer
• Participating Centers
• Key Personnel

            Protocol Chair: Julie Vose, MD (402-559-3848) jmvose@unmc.edu

            Protocol Officer: Marcie Tomblyn, MD (612-624-5109) tombl001@umn.edu

            Protocol Coordinator: Jennierose D’Elia (301-251-1161) jdelia@emmes.com

            Medical Monitor: Eneida Nemecek, MD nemeceke@ohsu.edu

The BMT CTN is committed to including widespread transplant community participation in these trials.  However, this study is nearing completion and no additional centers will be added.